Celyad « Terug naar discussie overzicht

Celyad 2021

3.900 Posts, Pagina: « 1 2 3 4 5 6 ... 188 189 190 191 192 193 194 195 » | Laatste
Garre
0
Gefeliciteerd groene appel, nu kopen kan ook geen kwaad, degene die ze al 3 jaar hebben die treuren met deze koers.
Maar ja ,dat is het risico, nog wat gehoord van je mails vanuit celyad?
Of waren ze weer thuis werken vanwege corona?
Maar geduld, er komt een dag dat we gaan knallen.
Hopende
0
quote:

Garre schreef op 28 december 2021 16:47:

Gefeliciteerd groene appel, nu kopen kan ook geen kwaad, degene die ze al 3 jaar hebben die treuren met deze koers.
Maar ja ,dat is het risico, nog wat gehoord van je mails vanuit celyad?
Of waren ze weer thuis werken vanwege corona?
Maar geduld, er komt een dag dat we gaan knallen.
mij antwoorden ze niet meer uit schaamte denk ik , wat een geblunder is me dat jong .
het aandeel volledig laten kapot gaan niet normaal , ik denk dat de grote investeerder toch ook eens slikt bij deze koers stand staat al bijna een € onder zijn aankoop prijs
groene appel
0
quote:

Garre schreef op 28 december 2021 16:47:

Gefeliciteerd groene appel, nu kopen kan ook geen kwaad, degene die ze al 3 jaar hebben die treuren met deze koers.
Maar ja ,dat is het risico, nog wat gehoord van je mails vanuit celyad?
Of waren ze weer thuis werken vanwege corona?
Maar geduld, er komt een dag dat we gaan knallen.
de mail is vandaag verstuurd.
Hopende
0
quote:

the Holy grail schreef op 28 december 2021 17:37:

weer een topdag voor mithra en celyad
Echt triestig
Garre
0
Toch niet te bevatten dit aandeel, en het gaat maar door.. niks hoor je uit celyad.
Zouden ze wel hun loonsverhogingen krijgen?
Hopende
0
quote:

the Holy grail schreef op 28 december 2021 17:37:

weer een topdag voor mithra en celyad
Bij mithra is er ook iets niet pluis
groene appel
0
Investment Analysts’ Weekly Ratings Changes for Celyad Oncology (CYAD)
Posted by ABMN Staff on Dec 28th, 2021



Celyad Oncology logoCelyad Oncology (NASDAQ: CYAD) recently received a number of ratings updates from brokerages and research firms:

12/24/2021 – Celyad Oncology was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. “
12/22/2021 – Celyad Oncology was downgraded by analysts at UBS Group AG from a “neutral” rating to a “sell” rating.
12/15/2021 – Celyad Oncology was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $4.75 price target on the stock. According to Zacks, “Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. “
12/10/2021 – Celyad Oncology had its price target lowered by analysts at HC Wainwright from $15.00 to $13.00. They now have a “buy” rating on the stock.
11/16/2021 – Celyad Oncology was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. “
11/15/2021 – Celyad Oncology was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $4.75 price target on the stock. According to Zacks, “Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. “
Shares of CYAD opened at $3.87 on Tuesday. The company has a quick ratio of 1.42, a current ratio of 0.97 and a debt-to-equity ratio of 0.10. The stock’s fifty day simple moving average is $4.23 and its 200 day simple moving average is $4.41. Celyad Oncology SA has a twelve month low of $3.53 and a twelve month high of $9.26.

Get Celyad Oncology SA alerts:
Enter Your Email Address

A hedge fund recently bought a new stake in Celyad Oncology stock. OLD Mission Capital LLC acquired a new stake in Celyad Oncology SA (NASDAQ:CYAD) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 11,323 shares of the company’s stock, valued at approximately $60,000. OLD Mission Capital LLC owned 0.07% of Celyad Oncology at the end of the most recent reporting period. 1.83% of the stock is owned by institutional investors and hedge funds.
Hopende
0
quote:

groene appel schreef op 28 december 2021 22:03:

Investment Analysts’ Weekly Ratings Changes for Celyad Oncology (CYAD)
Posted by ABMN Staff on Dec 28th, 2021



Celyad Oncology logoCelyad Oncology (NASDAQ: CYAD) recently received a number of ratings updates from brokerages and research firms:

12/24/2021 – Celyad Oncology was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. “
12/22/2021 – Celyad Oncology was downgraded by analysts at UBS Group AG from a “neutral” rating to a “sell” rating.
12/15/2021 – Celyad Oncology was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $4.75 price target on the stock. According to Zacks, “Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. “
12/10/2021 – Celyad Oncology had its price target lowered by analysts at HC Wainwright from $15.00 to $13.00. They now have a “buy” rating on the stock.
11/16/2021 – Celyad Oncology was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. “
11/15/2021 – Celyad Oncology was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $4.75 price target on the stock. According to Zacks, “Celyad SA is a biopharmaceutical company. The Company develops and commercializes cell based regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. Celyad SA is based in Mont-Saint-Guibert, Belgium. “
Shares of CYAD opened at $3.87 on Tuesday. The company has a quick ratio of 1.42, a current ratio of 0.97 and a debt-to-equity ratio of 0.10. The stock’s fifty day simple moving average is $4.23 and its 200 day simple moving average is $4.41. Celyad Oncology SA has a twelve month low of $3.53 and a twelve month high of $9.26.

Get Celyad Oncology SA alerts:
Enter Your Email Address

A hedge fund recently bought a new stake in Celyad Oncology stock. OLD Mission Capital LLC acquired a new stake in Celyad Oncology SA (NASDAQ:CYAD) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 11,323 shares of the company’s stock, valued at approximately $60,000. OLD Mission Capital LLC owned 0.07% of Celyad Oncology at the end of the most recent reporting period. 1.83% of the stock is owned by institutional investors and hedge funds.
daar kan je dus niets opbouwen hè , analist zijn is de meest overroepen job ter wereld .Bedragen zeggen die volledig uit d lucht zijn genomen en komen ze niet uit dat gaat er niemand je op de vingers tikken , volgens mij is Compleet zo een kadee
Hopende
1
Best wishes to you and your loved ones, and a special thank you to our team for a strong year of hard work! We appreciate the support from you all and hope you all have a new year of good health, happiness and prosperity
en een dikke merci voor alle eurootjes die we hebben mogen verbranden ( zal ons een zorg wezen zolang wij maar verder kunnen prutsen )
Hopende
0
Hopende
0
quote:

groene appel schreef op 29 december 2021 08:56:

wel een beetje positief het jaar uit he Hopende....
positief ? met celyad en mithra nog in portefeuille ? en met een overal verlies van 50 K sta ik er niet goed voor
Garre
0
the Holy grail
0
we gaan naar 3 , misschien ooit nog eens naar 3.5 bij een zoveelste korte heropleving en dan alles eruit
the Holy grail
0
je zou bang worden hier dat het half vier wordt hier , beste beslissing ooit om naar Amerika te trekken
Hopende
0
OMC zal wel een reden gehad om te investeren maar amaai is precies toch ook een serieuze gok van hun
3.900 Posts, Pagina: « 1 2 3 4 5 6 ... 188 189 190 191 192 193 194 195 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 29 sep 2022 17:35
Koers 1,490
Verschil 0,000 (0,00%)
Hoog 1,620
Laag 1,410
Volume 16.373
Volume gemiddeld 23.134
Volume gisteren 16.373

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront